First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
| Study Name | |
| First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT04526106 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| Please see clinicaltrials.gov | |
| Country | |
| United States | |
| Study Contacts | |
| Principal Investigator | |
| Please see clinicaltrials.gov | |
| P.I. Phone | |
| (339) 230-7475 | |
| P.I. Email | |
| ClinicalTrials@relaytx.com | |
| Study Coordinator | |
| Please see clinicaltrials.gov | |
| Study Coordinator Phone | |
| (339) 230-7475 | |
| Study Coordinator Email | |
| ClinicalTrials@relaytx.com | |
| OVERVIEW – in layman’s terms (150 words max) | |
| This clinical trial is studying the safety and effectiveness of an investigational drug for patients with Cholangiocarcinoma and other solid tumors that meet eligibility requirements. This investigational drug is a highly selective Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitor. Please refer to Clinicaltrials.gov for more information. | |
| Enrollment | |
| Ongoing | |
| Study Start Date | |
| 09/01/2020 | |
| Estimated Completion Date | |
| 10/01/2024 | |
